DK2361617T3 - Intraokulære implantater med depotpræparat omfattende en beta-adrenerg receptorantagonist og fremgangsmåder til behandling af okulære neuropatier - Google Patents

Intraokulære implantater med depotpræparat omfattende en beta-adrenerg receptorantagonist og fremgangsmåder til behandling af okulære neuropatier

Info

Publication number
DK2361617T3
DK2361617T3 DK11161473.1T DK11161473T DK2361617T3 DK 2361617 T3 DK2361617 T3 DK 2361617T3 DK 11161473 T DK11161473 T DK 11161473T DK 2361617 T3 DK2361617 T3 DK 2361617T3
Authority
DK
Denmark
Prior art keywords
repository
beta
methods
receptor antagonist
adrenergic receptor
Prior art date
Application number
DK11161473.1T
Other languages
English (en)
Inventor
Glenn T Huang
Thierry Nivaggioli
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of DK2361617T3 publication Critical patent/DK2361617T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
DK11161473.1T 2004-04-30 2005-04-21 Intraokulære implantater med depotpræparat omfattende en beta-adrenerg receptorantagonist og fremgangsmåder til behandling af okulære neuropatier DK2361617T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/836,880 US20050244458A1 (en) 2004-04-30 2004-04-30 Sustained release intraocular implants and methods for treating ocular neuropathies
EP05740148.1A EP1748766B1 (en) 2004-04-30 2005-04-21 Sustained release intraocular implants comprising a beta adrenergic receptor antagonist and methods for treating ocular neuropathies

Publications (1)

Publication Number Publication Date
DK2361617T3 true DK2361617T3 (da) 2014-09-22

Family

ID=34967183

Family Applications (1)

Application Number Title Priority Date Filing Date
DK11161473.1T DK2361617T3 (da) 2004-04-30 2005-04-21 Intraokulære implantater med depotpræparat omfattende en beta-adrenerg receptorantagonist og fremgangsmåder til behandling af okulære neuropatier

Country Status (9)

Country Link
US (3) US20050244458A1 (da)
EP (2) EP2361617B1 (da)
JP (2) JP2007535539A (da)
AU (1) AU2005244211B2 (da)
BR (1) BRPI0509339A (da)
CA (1) CA2565347C (da)
DK (1) DK2361617T3 (da)
ES (1) ES2499541T3 (da)
WO (1) WO2005110380A1 (da)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6726918B1 (en) 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
WO2002043785A2 (en) 2000-11-29 2002-06-06 Oculex Pharmaceuticals, Inc. Intraocular implants for preventing transplant rejection in the eye
US7431710B2 (en) 2002-04-08 2008-10-07 Glaukos Corporation Ocular implants with anchors and methods thereof
US20050048099A1 (en) 2003-01-09 2005-03-03 Allergan, Inc. Ocular implant made by a double extrusion process
US20050101582A1 (en) 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
US20070224278A1 (en) 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
AU2005209201B2 (en) 2004-01-20 2010-06-03 Allergan, Inc. Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid
US20050244463A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US8119154B2 (en) 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US20050244458A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular neuropathies
US8673341B2 (en) * 2004-04-30 2014-03-18 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
US9498457B2 (en) 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
US8529927B2 (en) * 2004-04-30 2013-09-10 Allergan, Inc. Alpha-2 agonist polymeric drug delivery systems
US20070212395A1 (en) * 2006-03-08 2007-09-13 Allergan, Inc. Ocular therapy using sirtuin-activating agents
US8147865B2 (en) * 2004-04-30 2012-04-03 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US7993634B2 (en) 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
TW200812575A (en) * 2006-04-28 2008-03-16 Alcon Inc Formulations containing amide derivatives of carboxylic acid NSAIDs for topical administration to the eye
US20070260203A1 (en) * 2006-05-04 2007-11-08 Allergan, Inc. Vasoactive agent intraocular implant
US8969415B2 (en) * 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
US8492334B2 (en) * 2007-06-21 2013-07-23 Yale University Sustained intraocular delivery of drugs from biodegradable polymeric microparticles
EP2050441A1 (en) * 2007-10-19 2009-04-22 Université Victor Segalen Bordeaux 2 Use of beta blocker for the manufacture of a medicament for the treatment of hemangiomas
US9877973B2 (en) * 2008-05-12 2018-01-30 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US10064819B2 (en) 2008-05-12 2018-09-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US10588855B2 (en) 2008-05-12 2020-03-17 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US9095506B2 (en) 2008-11-17 2015-08-04 Allergan, Inc. Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof
EP3412260B1 (en) 2009-05-18 2020-08-26 Dose Medical Corporation Drug eluting ocular implant
US12478503B2 (en) 2009-05-18 2025-11-25 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
AU2010314990B2 (en) 2009-11-09 2015-10-01 Allergan, Inc. Compositions and methods for stimulating hair growth
EP2654715B1 (en) 2010-11-24 2017-01-25 Dose Medical Corporation Drug eluting ocular implant
US8349005B2 (en) 2011-01-03 2013-01-08 Masatoshi Murata Method for burying implant to choroid
US10245178B1 (en) 2011-06-07 2019-04-02 Glaukos Corporation Anterior chamber drug-eluting ocular implant
US20140234389A1 (en) 2013-02-15 2014-08-21 Allergan, Inc. Sustained drug delivery implant
ES2805880T3 (es) 2013-10-31 2021-02-15 Allergan Inc Implantes intraoculares que contienen prostamida y métodos de uso de éstos
US20150342875A1 (en) 2014-05-29 2015-12-03 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
US11925578B2 (en) 2015-09-02 2024-03-12 Glaukos Corporation Drug delivery implants with bi-directional delivery capacity
WO2017053885A1 (en) 2015-09-25 2017-03-30 Glaukos Corporation Punctal implants with controlled drug delivery features and methods of using same
US20170133284A1 (en) * 2015-11-05 2017-05-11 Texas Instruments Incorporated Smart in-situ chamber clean
JP7003110B2 (ja) 2016-04-20 2022-01-20 ドーズ メディカル コーポレーション 生体吸収性眼球薬物送達デバイス
KR102520771B1 (ko) 2016-09-23 2023-04-12 인셉트, 엘엘씨 전안방내 약물 전달 데포
AU2020302924A1 (en) 2019-06-27 2022-02-17 Layerbio, Inc. Ocular device delivery methods and systems
TW202207943A (zh) * 2020-05-21 2022-03-01 美商灰色視覺公司 用於長期眼部治療之耐久植入物及微粒

Family Cites Families (149)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4006864A (en) * 1973-11-27 1977-02-08 Daiwa Boseki Kabushiki Kaisha Method and apparatus for carrying out doffing and donning operation
SE390255B (sv) * 1974-02-18 1976-12-13 N G Y Torphammar Upprullningsanordning foretredesvis for ett sekerhetsbelte i ett fordon
GB1478759A (en) * 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US3966749A (en) * 1975-02-10 1976-06-29 Interx Research Corporation Novel synthesis of optically active m-acyloxy-α-[(methylamino)methyl]benzyl alcohols, the pharmaceutically acceptable acid addition salts thereof and intermediate useful in the preparation thereof
US4014335A (en) * 1975-04-21 1977-03-29 Alza Corporation Ocular drug delivery device
US4052505A (en) * 1975-05-30 1977-10-04 Alza Corporation Ocular therapeutic system manufactured from copolymer
US4144317A (en) * 1975-05-30 1979-03-13 Alza Corporation Device consisting of copolymer having acetoxy groups for delivering drugs
US4057619A (en) * 1975-06-30 1977-11-08 Alza Corporation Ocular therapeutic system with selected membranes for administering ophthalmic drug
US4063064A (en) * 1976-02-23 1977-12-13 Coherent Radiation Apparatus for tracking moving workpiece by a laser beam
US4186184A (en) * 1977-12-27 1980-01-29 Alza Corporation Selective administration of drug with ocular therapeutic system
US4190642A (en) * 1978-04-17 1980-02-26 Alza Corporation Ocular therapeutic system for dispensing a medication formulation
US4200098A (en) 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4285987A (en) 1978-10-23 1981-08-25 Alza Corporation Process for manufacturing device with dispersion zone
US4303637A (en) 1980-04-04 1981-12-01 Alza Corporation Medication indicated for ocular hypertension
US4281654A (en) 1980-04-07 1981-08-04 Alza Corporation Drug delivery system for controlled ocular therapy
US4396625A (en) 1980-05-13 1983-08-02 Sumitomo Chemical Company, Limited Treatment of glaucoma or ocular hypertension and ophthalmic composition
US4425348A (en) * 1980-05-16 1984-01-10 Bristol-Myers Company Antitumor compositions
US4425346A (en) 1980-08-01 1984-01-10 Smith And Nephew Associated Companies Limited Pharmaceutical compositions
US4304765A (en) 1980-10-14 1981-12-08 Alza Corporation Ocular insert housing steroid in two different therapeutic forms
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
JPS58126435U (ja) 1982-02-19 1983-08-27 オリンパス光学工業株式会社 Ｔｔｌオ−トストロボ用絞り制御回路
US4599353A (en) 1982-05-03 1986-07-08 The Trustees Of Columbia University In The City Of New York Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma
DE3220156C2 (de) 1982-05-28 1990-01-25 Heida Houston Tex. Thurlow Mit Metallgriffen, insbesondere Edelstahlgriffen, versehenes Koch- und Bratgeschirr mit Deckel
US4649151A (en) 1982-09-27 1987-03-10 Health Research, Inc. Drugs comprising porphyrins
US4478818A (en) 1982-12-27 1984-10-23 Alza Corporation Ocular preparation housing steroid in two different therapeutic forms
US4521210A (en) 1982-12-27 1985-06-04 Wong Vernon G Eye implant for relieving glaucoma, and device and method for use therewith
US6309669B1 (en) 1984-03-16 2001-10-30 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix
US4693885A (en) 1984-07-18 1987-09-15 Nippon Petrochemicals Co., Ltd. Tetrapyrrole therapeutic agents
US4675338A (en) 1984-07-18 1987-06-23 Nippon Petrochemicals Co., Ltd. Tetrapyrrole therapeutic agents
FR2577509B1 (fr) 1985-02-21 1987-05-07 Nirvana Espar Systems Sa Mat de bateau a voile
US4656186A (en) 1985-04-30 1987-04-07 Nippon Petrochemicals Co., Ltd. Tetrapyrrole therapeutic agents
US4668506A (en) 1985-08-16 1987-05-26 Bausch & Lomb Incorporated Sustained-release formulation containing and amino acid polymer
FR2594438B1 (fr) 1986-02-14 1990-01-26 Labaz Sanofi Nv Derives d'indolizine, leur procede de preparation ainsi que les compositions en contenant
US4959217A (en) 1986-05-22 1990-09-25 Syntex (U.S.A.) Inc. Delayed/sustained release of macromolecules
US4863457A (en) 1986-11-24 1989-09-05 Lee David A Drug delivery device
US5089509A (en) 1988-09-15 1992-02-18 Allergan, Inc. Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity
US4981871A (en) 1987-05-15 1991-01-01 Abelson Mark B Treatment of ocular hypertension with class I calcium channel blocking agents
DE3734223A1 (de) 1987-10-09 1989-04-20 Boehringer Ingelheim Kg Implantierbares, biologisch abbaubares wirkstofffreigabesystem
US4853224A (en) 1987-12-22 1989-08-01 Visionex Biodegradable ocular implants
US4997652A (en) * 1987-12-22 1991-03-05 Visionex Biodegradable ocular implants
US4865846A (en) 1988-06-03 1989-09-12 Kaufman Herbert E Drug delivery system
US4968715A (en) 1988-07-06 1990-11-06 Health Research, Inc. Use of purified hematoporphyrin trimers in photodynamic therapy
US5190966A (en) 1988-07-06 1993-03-02 Health Research, Inc. Purified hematoporphyrin dimers and trimers useful in photodynamic therapy
US5002962A (en) 1988-07-20 1991-03-26 Health Research, Inc. Photosensitizing agents
US5198460A (en) 1988-07-20 1993-03-30 Health Research Inc. Pyropheophorbides and their use in photodynamic therapy
US5093349A (en) 1988-07-20 1992-03-03 Health Research Inc. Photosensitizing agents
DE1300150T1 (de) 1988-09-06 2003-09-18 Pharmacia Ab, Stockholm Prostaglandin-Derivate zur Behandlung von Glaukom oder Augenüberdruck
US5702716A (en) * 1988-10-03 1997-12-30 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
US4935498A (en) 1989-03-06 1990-06-19 Board Of Regents, The University Of Texas System Expanded porphyrins: large porphyrin-like tripyrroledimethine-derived macrocycles
US5457183A (en) 1989-03-06 1995-10-10 Board Of Regents, The University Of Texas System Hydroxylated texaphyrins
US5171741A (en) 1989-04-21 1992-12-15 Health Research, Inc. Bacteriochlorophyll-a derivatives useful in photodynamic therapy
US5173504A (en) 1989-04-21 1992-12-22 Health Research, Inc. Bacteriochlorophyll-a derivatives useful in photodynamic therapy
US5019400A (en) 1989-05-01 1991-05-28 Enzytech, Inc. Very low temperature casting of controlled release microspheres
US5034413A (en) 1989-07-27 1991-07-23 Allergan, Inc. Intraocular pressure reducing 9,11-diacyl prostaglandins
US5268178A (en) 1989-09-25 1993-12-07 The Board Of Regents, The University Of Texas System Biodegradable antibiotic implants and methods of their use in treating and preventing infections
US5503721A (en) 1991-07-18 1996-04-02 Hri Research, Inc. Method for photoactivation
US5164188A (en) * 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
US5075115A (en) 1990-04-02 1991-12-24 Fmc Corporation Process for polymerizing poly(lactic acid)
US5232844A (en) 1990-05-15 1993-08-03 New York Blood Center Photodynamic inactivation of viruses in cell-containing compositions
US5095031A (en) * 1990-08-20 1992-03-10 Abbott Laboratories Indole derivatives which inhibit leukotriene biosynthesis
US5100431A (en) 1990-09-27 1992-03-31 Allergan, Inc. Single stitch suture needle and method
KR0185215B1 (ko) * 1990-11-30 1999-05-01 요시다 쇼오지 서방성 안구삽입용 약제
US5275820A (en) 1990-12-27 1994-01-04 Allergan, Inc. Stable suspension formulations of bioerodible polymer matrix microparticles incorporating drug loaded ion exchange resin particles
US5378475A (en) * 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
KR0145278B1 (ko) 1991-06-21 1998-07-15 브루스 엠. 에이센 골형성원 단백질 약제
US5356629A (en) 1991-07-12 1994-10-18 United States Surgical Corporation Composition for effecting bone repair
US5169638A (en) 1991-10-23 1992-12-08 E. R. Squibb & Sons, Inc. Buoyant controlled release powder formulation
US5543154A (en) 1991-12-27 1996-08-06 Merck & Co., Inc. Controlled release nifedipine delivery device
US5656297A (en) 1992-03-12 1997-08-12 Alkermes Controlled Therapeutics, Incorporated Modulated release from biocompatible polymers
IT1263116B (it) 1992-04-09 1996-07-30 Rotta Research Lab Derivati basici dell'acido glutammico ed acido aspartico, procedimento per la loro preparazione e loro uso farmaceutico
US5655832A (en) 1992-04-16 1997-08-12 Tir Technologies, Inc. Multiple wavelength light processor
US5244914A (en) 1992-04-27 1993-09-14 American Cyanamid Company Stable porfimer sodium compositions and methods for their manufacture
US5178635A (en) 1992-05-04 1993-01-12 Allergan, Inc. Method for determining amount of medication in an implantable device
US5629008A (en) * 1992-06-02 1997-05-13 C.R. Bard, Inc. Method and device for long-term delivery of drugs
US6217869B1 (en) 1992-06-09 2001-04-17 Neorx Corporation Pretargeting methods and compounds
US5688819A (en) 1992-09-21 1997-11-18 Allergan Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5972991A (en) 1992-09-21 1999-10-26 Allergan Cyclopentane heptan(ene) oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US5922773A (en) 1992-12-04 1999-07-13 The Children's Medical Center Corp. Glaucoma treatment
US5707643A (en) 1993-02-26 1998-01-13 Santen Pharmaceutical Co., Ltd. Biodegradable scleral plug
US5770589A (en) 1993-07-27 1998-06-23 The University Of Sydney Treatment of macular degeneration
US5504074A (en) 1993-08-06 1996-04-02 Children's Medical Center Corporation Estrogenic compounds as anti-angiogenic agents
US5385887A (en) 1993-09-10 1995-01-31 Genetics Institute, Inc. Formulations for delivery of osteogenic proteins
US5443505A (en) 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US6051576A (en) 1994-01-28 2000-04-18 University Of Kentucky Research Foundation Means to achieve sustained release of synergistic drugs by conjugation
DE4403326C1 (de) 1994-02-03 1995-06-22 Hans Reinhard Prof Dr Koch Intraokulare Linsenanordnung zur Astigmatismuskorrektur
US5798349A (en) 1994-03-14 1998-08-25 The General Hospital Corporation Use of green porphyrins to treat neovasculature in the eye
US5466233A (en) 1994-04-25 1995-11-14 Escalon Ophthalmics, Inc. Tack for intraocular drug delivery and method for inserting and removing same
US6290991B1 (en) 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
US6270492B1 (en) 1994-09-09 2001-08-07 Cardiofocus, Inc. Phototherapeutic apparatus with diffusive tip assembly
US5869079A (en) 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US6369116B1 (en) * 1995-06-02 2002-04-09 Oculex Pharmaceuticals, Inc. Composition and method for treating glaucoma
US5906920A (en) 1995-08-29 1999-05-25 The Salk Institute For Biological Studies Methods for the detection of ligands for retinoid X receptors
US5958954A (en) 1995-09-01 1999-09-28 Allergan Sales, Inc. Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
US5776699A (en) 1995-09-01 1998-07-07 Allergan, Inc. Method of identifying negative hormone and/or antagonist activities
US5877207A (en) 1996-03-11 1999-03-02 Allergan Sales, Inc. Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
WO1998010758A1 (en) 1996-09-13 1998-03-19 The Regents Of The University Of California Methods for treatment of retinal diseases
US5913884A (en) 1996-09-19 1999-06-22 The General Hospital Corporation Inhibition of fibrosis by photodynamic therapy
US6270749B1 (en) 1996-12-11 2001-08-07 Pharmacyclics, Inc. Use of Texaphyrin in ocular diagnosis and therapy
US6274614B1 (en) 1997-02-11 2001-08-14 Qlt Inc. Methods, compositions and articles for reducing or preventing the effects of inflammation
US5932236A (en) * 1997-03-06 1999-08-03 Bass; James S. Pharmaceutical composition and methods for using it
US5919970A (en) 1997-04-24 1999-07-06 Allergan Sales, Inc. Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity
US5913864A (en) * 1997-06-09 1999-06-22 Garito; Jon C. Electrosurgical dermatological curet
AU727080B2 (en) 1997-06-30 2000-11-30 Allergan, Inc. Calcium blockers to treat proliferative vitreoretinopathy
AU738338B2 (en) 1997-08-11 2001-09-13 Allergan, Inc. Sterile bioerodible implant device with improved biocompatability and method
US6306426B1 (en) 1997-08-11 2001-10-23 Allergan Sales, Inc. Implant device with a retinoid for improved biocompatibility
US6271220B1 (en) 1998-03-11 2001-08-07 Allergan Sales, Inc. Anti-angiogenic agents
EP1100366B1 (en) 1998-07-09 2009-04-15 Curelight Medical Ltd Apparatus and method for efficient high energy photodynamic therapy of acne vulgaris and seborrhea
SE9803662D0 (sv) * 1998-10-26 1998-10-26 Pharmacia & Upjohn Ab Autoinjector
EP1131114B1 (en) 1998-11-20 2004-06-16 The University of Connecticut Apparatus and method for control of tissue/implant interactions
US20020197300A1 (en) 1999-02-22 2002-12-26 Schultz Clyde L. Drug delivery system for anti-glaucomatous medication
US6217895B1 (en) 1999-03-22 2001-04-17 Control Delivery Systems Method for treating and/or preventing retinal diseases with sustained release corticosteroids
US6482854B1 (en) 1999-03-25 2002-11-19 Massachusetts Eye And Ear Infirmary Glaucoma treatment
US6217896B1 (en) * 1999-04-01 2001-04-17 Uab Research Foundation Conjunctival inserts for topical delivery of medication or lubrication
US6290713B1 (en) 1999-08-24 2001-09-18 Thomas A. Russell Flexible illuminators for phototherapy
US6317616B1 (en) 1999-09-15 2001-11-13 Neil David Glossop Method and system to facilitate image guided surgery
US6331313B1 (en) * 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
US6319273B1 (en) 1999-12-16 2001-11-20 Light Sciences Corporation Illuminating device for treating eye disease
DE60135633D1 (de) 2000-02-10 2008-10-16 Massachusetts Eye & Ear Infirm Photodynamische therapie zur behandlung von augenerkrankungen
US20020143284A1 (en) * 2001-04-03 2002-10-03 Hosheng Tu Drug-releasing trabecular implant for glaucoma treatment
US20040208910A1 (en) 2000-04-26 2004-10-21 Control Delivery Systems, Inc. Sustained release device and method for ocular delivery of adrenergic agents
US6726918B1 (en) 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
PE20020146A1 (es) 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
US6357568B1 (en) 2000-09-27 2002-03-19 Shou Mao Chen Structure for protecting a luggage shell
AU2002248284A1 (en) 2000-11-01 2002-08-06 Allergan, Inc. Compositions for treatment of ocular neovascularization
WO2002043785A2 (en) 2000-11-29 2002-06-06 Oculex Pharmaceuticals, Inc. Intraocular implants for preventing transplant rejection in the eye
US6595945B2 (en) 2001-01-09 2003-07-22 J. David Brown Glaucoma treatment device and method
WO2002062423A1 (en) * 2001-02-02 2002-08-15 Bristol-Myers Squibb Company Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US6713081B2 (en) 2001-03-15 2004-03-30 The United States Of America As Represented By The Department Of Health And Human Services Ocular therapeutic agent delivery devices and methods for making and using such devices
TWI298257B (en) 2001-05-31 2008-07-01 Allergan Inc Hypotensive lipid and timolol compositions and methods of using same
US6713268B2 (en) 2001-06-26 2004-03-30 Allergan, Inc. Methods of identifying ocular hypotensive compounds having reduced hyperpigmentation
GB0122318D0 (en) * 2001-09-14 2001-11-07 Novartis Ag Organic compounds
CA2461812C (en) 2001-09-27 2011-09-20 Allergan, Inc. 3-(arylamino)methylene-1,3-dihydro-2h-indol-2-ones as kinase inhibitors
US20030114460A1 (en) 2001-12-14 2003-06-19 Allergan Sales, Inc. Pharmaceutical conjugates with enhanced pharmacokinetic characteristics
WO2003061625A2 (en) * 2002-01-18 2003-07-31 Snyder Michael E Sustained release ophthalmological device and method of making and using the same
US20030165545A1 (en) 2002-01-30 2003-09-04 Allergan, Inc. Ophthalmic compositions including oil-in-water emulsions, and methods for making and using same
US7030149B2 (en) 2002-04-19 2006-04-18 Allergan, Inc. Combination of brimonidine timolol for topical ophthalmic use
US6899717B2 (en) 2002-09-18 2005-05-31 Allergan, Inc. Methods and apparatus for delivery of ocular implants
CN1713890A (zh) * 2002-11-06 2005-12-28 阿尔萨公司 控释储库制剂
US20040137059A1 (en) * 2003-01-09 2004-07-15 Thierry Nivaggioli Biodegradable ocular implant
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US8147865B2 (en) 2004-04-30 2012-04-03 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US20050244465A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Drug delivery systems and methods for treatment of an eye
US20050244458A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular neuropathies
US20050244469A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
US20070238732A1 (en) 2006-04-10 2007-10-11 Allergan, Inc. Brimonidine and timolol compositions
WO2011087790A1 (en) 2009-12-22 2011-07-21 Allergan, Inc. Triple combination for lowering intraocular pres sure
BR112012025581A2 (pt) 2010-04-06 2019-09-24 Allergan Inc implantes de reservatório de liberação sustentada para distribuição de fármaco intracameral

Also Published As

Publication number Publication date
ES2499541T3 (es) 2014-09-29
AU2005244211A1 (en) 2005-11-24
BRPI0509339A (pt) 2007-07-24
US20050244458A1 (en) 2005-11-03
WO2005110380A1 (en) 2005-11-24
JP2013126997A (ja) 2013-06-27
EP1748766A1 (en) 2007-02-07
AU2005244211B2 (en) 2011-05-26
US8715709B2 (en) 2014-05-06
CA2565347C (en) 2014-01-28
EP1748766B1 (en) 2014-06-11
EP2361617B1 (en) 2014-06-11
CA2565347A1 (en) 2005-11-24
EP2361617A1 (en) 2011-08-31
US20140199366A1 (en) 2014-07-17
JP2007535539A (ja) 2007-12-06
US20110091520A1 (en) 2011-04-21

Similar Documents

Publication Publication Date Title
DK2361617T3 (da) Intraokulære implantater med depotpræparat omfattende en beta-adrenerg receptorantagonist og fremgangsmåder til behandling af okulære neuropatier
IL161706A0 (en) Intraocular lens fixation device
DK2952178T3 (da) Oftalmiske sammensætninger og fremgangsmåder til behandling af øjne
EP1740193A4 (en) PROLONGED RELEASE IMPLANTS CONTAINING MACROMOLECULES AND METHODS THEREOF
IL179700A0 (en) Ocular implant and methods for making and using same
DK1610691T3 (da) Indretning til placering af et vaskulært implantat
NO20050934L (no) Fremgangsmater og apparat for avlevering av okulare implantater
ATE432056T1 (de) Zervikale zwischenwirbelprothese
FR2870106B1 (fr) Implant intervertebral
IL182938A0 (en) Electro-active intraocular lenses
EP1877010A4 (en) INTERVERTEBRAL IMPLANT
DK1802334T3 (da) Fremgangsmåde til behandling af intraokulære, neovaskulære sygdomme
DK1684663T3 (da) Bækkenimplantat med forankringsramme
EP1768630A4 (en) TISSUE GRAFT PROCESSING TECHNOLOGY
DK2298237T3 (da) Hjerteprotese
EP2007322A4 (en) POSTERIORE SPINAL DEVICE AND METHOD
FR2841767B1 (fr) Lentille intraoculaire accommodative
FR2871678B1 (fr) Prothese totale du genou
DK1592408T3 (da) Indretning med depotvirkning og fremgangsmåde til okulær indgivelse af adrenergt midler
DK1759702T3 (da) Fremgangsmåde til fremstilling af en latanoprost-öjenoplösning og en således fremstillet oplösning
EP1774395A4 (en) GLASS STRUCTURES, GLASSES USING THE SAME, METHOD FOR MANUFACTURING SAME, AND PROGRAMMED MACHINE FOR FORMING THE SAME
DE602005003462D1 (de) Hilfsanordnung zur implantation von knieprothesen
DK2163248T3 (da) Benzothiazepinderivater som ryanodinreceptor-(RYR2)-inhibitorer og deres anvendelse til behandling af hjertesygdomme
DE602005002498D1 (de) Gehirnimplantat
DK1629960T3 (da) Fremgangsmåde og forme til fremstilling af oftalmiske linser